Showing 4441-4450 of 9330 results for "".
- Galderma Launches Three New DTC Campaignshttps://practicaldermatology.com/news/galderma-launches-three-new-dtc-campaigns/2458673/Galderma is rolling out three new direct-to-consumer creative campaigns designed to educate consumers and support Dysport® and Restylane® Silk. The campaigns, which feature unretouched photography, will be supported by significant print, digital and co-op advertising investments. Each campaign tel…
- Provectus Biopharmaceuticals Announces Leadership Changeshttps://practicaldermatology.com/news/provectus-biopharmaceuticals-announces-leadership-changes/2458674/Provectus Biopharmaceuticals, Inc. detailed several leadership changes following the resignation of one of its Co-Founders and its Chairman and CEO, H. Craig Dees, PhD. The Provectus Board of Directors accepted the resignation of Dr. Dees, which he submitted due to personal and health reasons, in a…
- Grooming Habits, Products May Affect Alopecia Riskhttps://practicaldermatology.com/news/grooming-habits-products-may-affect-alopecia-risk/2458671/Environmental factors --including weathering and grooming habits – may play a role in causing age-related alopecia, according to a new report in the International Journal of Women’s Dermatology. The report, called What Ages Hair?, suggests that aging of hair is determined by an interplay of many …
- Cipher Launches Bionect Foamhttps://practicaldermatology.com/news/cipher-launches-bionect-foam/2458678/Cipher Pharmaceuticals’ prescription topical Bionect® is now available in the US in a lightweight foam preparation that holds its shape until application. The company says the formulation makes it easier for dermatologists to treat hard-to-reach skin areas. Bionect® Foam has the same moisturizin…
- Galderma to Begin Two Phase III Restylane Trialshttps://practicaldermatology.com/news/galderma-to-begins-two-phase-iii-restylane-trials/2458679/Galderma is set to initiate a pivotal Phase III trial on Restylane® Lyft for hand augmentation and another that will look to the safety of Restylane® Silk when administered via cannula for perioral rejuvenation. Restylane® Lyft Hand Rejuvenation Study The pivotal Phase III trial is a randomize…
- Pioneer in Laser Development to Give Keynote at ASLMS 2016https://practicaldermatology.com/news/pioneer-in-laser-development-to-give-keynote-at-aslms-2016/2458682/Robert Afzal, PhD, a leading expert in high power fiber laser development, will deliver the keynote address at ASLMS 2016, the Annual Conference of the American Society for Laser Medicine & Surgery, Inc. (ASLMS), to be held in Boston, Massachusetts March 30 – April 2, 2016. Dr. Afzal will present "…
- FDA Approves Allergan's Aczone Gel, 7.5% for Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-allergans-aczone-gel-75-for-acne-vulgaris/2458681/The FDA approved Allergn’s Aczone (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older. Aczone Gel, 7.5% delivers proven efficacy to treat both inflammatory and non-inflammatory acne, with a new concentration of dapsone in just once-a-day applicat…
- Neutrogena® Launches First-Ever Global Beauty Campaignhttps://practicaldermatology.com/news/neutrogena-launches-first-ever-global-beauty-campaign/2458684/Neutrogena® is set to debut their first-ever global campaign: “Neutrogena. See What’s Possible.™” A commercial voiced by Brand Ambassador and creative consultant Kerry Washington will feature real women following their passions. In addition, the campaign includes digital content leveraged through…
- WHO: Improved Access to Psoriasis Treatments Neededhttps://practicaldermatology.com/news/who-improved-access-to-psoriasis-treatments-needed/2458685/Key stakeholders including policy makers, physicians and patients must come together to turn the corner on psoriasis, according to the World Health Organization’s (WHO) new Global Report on Psoriasis. In 2014, the WHO Member States recognized psoriasis as a serious non-communicable disease. A byp…
- CMS: 2015 Hardship Exemption Does Not Impede EHR Incentiveshttps://practicaldermatology.com/news/cms-2015-hardship-exemption-does-not-impede-her-incentives/2458686/The Centers for Medicare & Medicaid Services (CMS) has released a new frequently asked question (FAQ) to help clarify the 2015 hardship exemption. In sum, providers who submit a hardship exception application may still attest to the Medicare Electronic Health Record (EHR) Incentive Program for the…